更新于：2024-07-03
Docetaxel albumin bound
多西他赛（白蛋白结合型）
更新于：2024-07-03
概要
基本信息
非在研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
关联
26
项与 多西他赛（白蛋白结合型） 相关的临床试验A Randomized, Controlled, Open-label Phase II/III Study of The Safety, Tolerability and Efficacy of JMT101 Combined With Docetaxel / HB1801 in Patients With sqNSCLC
注射用多西他赛（白蛋白结合型）对比泰索帝®治疗既往一线治疗失败的局部晚期或转移性胃腺癌或胃食管结合部腺癌的多中心、随机、开放、阳性对照III期临床研究
A Multicenter, Randomized, Controlled Phase III Clinical Study of Docetaxel for Injection (Albumin-bound) Versus Taxotere in Gastric Cancer
100 项与 多西他赛（白蛋白结合型） 相关的临床结果
登录后查看更多信息
100 项与 多西他赛（白蛋白结合型） 相关的转化医学
登录后查看更多信息
100 项与 多西他赛（白蛋白结合型） 相关的专利（医药）
登录后查看更多信息
15
项与 多西他赛（白蛋白结合型） 相关的文献（医药）2023-03-15BMC cancer
Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.
Article
作者: Jiang, Ke ; Yang, Kunyu ; Huang, Ai ; Yang, Jinsong
BACKGROUND:
The failure rate after neoadjuvant chemoradiotherapy followed by surgery is approximately 34.6%-48% for resectable esophageal carcinoma. Pathologic complete response after neoadjuvant chemoradiotherapy is an important factor in predicting lower recurrence and better survival. Whether the sequential addition of immunotherapy to neoadjuvant chemoradiotherapy will be beneficial to improving the pathologic complete response rate is unknown.
METHODS:
Patients with pathologically confirmed thoracic esophageal squamous cell carcinoma and at clinical T1-2N1-3M0 or T3-4aN0-3M0 (stage II-IVA) according to the eighth edition of American Joint Committee on Cancer staging will be allocated to receive neoadjuvant radiotherapy (41.4 Gy with 23 fractions to planning target volume) with concurrent chemotherapy (albumin-bound paclitaxel, 100 mg/m2, once weekly for five weeks; carboplatin, area under the curve of 2 mg/mL/min, once weekly for five weeks) plus tislelizumab monotherapy sequentially (200 mg every three weeks for three cycles, beginning from the first to the 14th day after the end of radiotherapy). Then, subtotal esophagectomy with two-field lymphadenectomy, including the whole mediastinum and abdomen, will be performed. The primary endpoint for this study is the pathologic complete response rate after neoadjuvant chemoradiotherapy plus tislelizumab.
DISCUSSION:
The optimal timing of the combination of immunotherapy and neoadjuvant chemoradiotherapy in esophageal carcinoma is not determined. The results of this phase II trial will be helpful to clarify the safety and efficacy of the sequential addition of tislelizumab after neoadjuvant chemoradiotherapy for locally advanced resectable esophageal carcinoma.
TRIAL REGISTRATION:
This study was approved on January 26, 2021 and retrospectively registered with ClinicalTrials.gov ( NCT04776590 ) on March 1, 2021.
2022-12-01Journal of nanobiotechnology
Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations
Article
作者: Ye, Peng ; Guo, Peilin ; Ma, Guanghui ; Chai, Ningli ; Zou, Jiale ; Wei, Bo ; Yue, Hua ; Linghu, Enqiang ; Wei, Wei ; Wang, Shuang ; Li, Feng
Abstract:
Background:
Gastric cancer (GC) is a highly heterogeneous disease with many different histological and molecular subtypes. Due to their reduced systemic adverse effects, nanoformulation agents have attracted increasing attention for use in the treatment of GC patients in the clinic. To improve therapeutic outcomes, it is vitally necessary to provide individual medication references and guidance for use of these nanoformulations, and patient-derived organoids (PDOs) are promising models through which to achieve this goal.
Results:
Using an improved enzymatic digestion process, we succeeded in constructing GC PDOs from surgically resected tumor tissues and endoscopic biopsies from GC patients; these PDOs closely recapitulated the histopathological and genomic features of the corresponding primary tumors. Next, we chose two representative paclitaxel (PTX) nanoformulations for comparative study and found that liposomal PTX outperformed albumin-bound PTX in killing GC PDOs at both the transcriptome and cellular levels. Our results further showed that the different distributions of liposomal PTX and albumin-bound PTX in PDOs played an essential role in the distinct mechanisms through which they kill PDOs. Finally, we constructed patient-derived xenografts model in which we verified the above distinct therapeutic outcomes via an intratumoral administration route.
Conclusions:
This study demonstrates that GC PDOs are reliable tools for predicting nanoformulation efficacy.
Graphical Abstract:
2021-06-01Annals of palliative medicine4区 · 医学
Complete and enduring response in an elderly patient with repeated recurrent gingival squamous cell carcinoma treated by combined toripalimab and single agent chemotherapy: a case report
4区 · 医学
Article
作者: Zhang, Shuyuan ; Hua, Xinying ; Wu, Qiuji ; Zhong, Yahua ; Yu, Haijun
Combined immune checkpoint inhibitor with platinum-based doublet chemotherapy brought about significant improvement in overall survival as the first line treatment in metastatic and recurrent head and neck cancer patients. However, in elderly patients with relatively poor performance status, these regimens might not be well tolerated. Therefore, we evaluated the safety and effect of combined immunotherapy and single agent chemotherapy in an elderly patient with recurrent head and neck squamous cell carcinoma. A 78-year-old male patients with a repeatedly recurrent gingival squamous cell carcinoma was admitted in our institute. Previously this patient underwent two consecutive surgical resections of recurrent tumors before the second rapid recurrence that resulted in extended tumor mass and lymph node metastasis. As the patient was in a relatively poor performance status (performance status =2), immunotherapy with PD-1 antibody (Toripalimab) combined with single agent chemotherapy (two cycle with albumin-bound paclitaxel and then six cycles with gemcitabine) was administrated, which led to clinical complete response after 8 cycles of treatment. The patient continued 4 cycles of maintenance immunotherapy with Toripalimab until the outbreak of the coronavirus disease 2019. The treatment was well tolerated and the patient remained free from disease until the last follow up by June 2020, 16 months after the initiation of treatment. The success in this case indicated that the combination of anti-PD-1 antibody and single chemotherapy agent may also be effective as well as safe in elderly patients with recurrent head and neck squamous cell carcinoma.
100 项与 多西他赛（白蛋白结合型） 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃食管交界处腺癌 | 临床3期 | 中国 | 2024-03-15 | |
| 胃腺癌 | 临床3期 | 中国 | 2024-03-15 | |
| HER2阳性乳腺癌 | 临床3期 | - | 2023-07-01 | |
| c-Met阳性非小细胞肺癌 | 临床2期 | 中国 | 2024-07-02 | |
| 局部晚期食管鳞状细胞癌 | 临床2期 | 中国 | 2023-12-01 | |
| 食管鳞状细胞癌 | 临床2期 | 中国 | 2023-11-27 | |
| 局部晚期非小细胞肺癌 | 临床2期 | 中国 | 2023-06-27 | |
| 胰腺癌 | 临床2期 | 中国 | 2022-12-26 | |
| 复发性卵巢癌 | 临床2期 | 中国 | 2022-08-18 | |
| 转移性乳腺癌 | 临床2期 | 美国 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 125 | HB1801 (albumin-bound docetaxel) | 構構獵鑰築艱齋鏇齋淵(觸繭廠襯鹽膚鹹鏇壓壓) = 簾廠衊憲鬱鑰淵窪壓願 齋製簾構鹹艱壓繭鏇夢 (獵廠襯襯遞願鏇憲窪願, 42.15 ~ 72.34) 更多 | 积极 | 2024-05-24 | ||
Docetaxel (Taxotere) | 構構獵鑰築艱齋鏇齋淵(觸繭廠襯鹽膚鹹鏇壓壓) = 襯鑰築築夢膚衊網遞壓 齋製簾構鹹艱壓繭鏇夢 (獵廠襯襯遞願鏇憲窪願, 32.11 ~ 61.92) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用